ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $46,237,500 | +560.2% | 1,125,000 | +650.0% | 0.09% | +561.5% |
Q1 2024 | $7,003,500 | -85.7% | 150,000 | -85.4% | 0.01% | -87.1% |
Q4 2023 | $49,015,500 | +1427.7% | 1,025,000 | +1038.9% | 0.10% | +1342.9% |
Q3 2023 | $3,208,500 | -35.4% | 90,000 | -16.4% | 0.01% | -36.4% |
Q2 2023 | $4,963,588 | +1.5% | 107,600 | -11.8% | 0.01% | 0.0% |
Q1 2023 | $4,892,200 | -24.6% | 122,000 | -12.9% | 0.01% | -31.2% |
Q4 2022 | $6,486,200 | +1.0% | 140,000 | -9.7% | 0.02% | 0.0% |
Q3 2022 | $6,421,000 | -84.2% | 155,062 | -77.2% | 0.02% | -82.8% |
Q2 2022 | $40,569,000 | -20.2% | 680,000 | -2.9% | 0.09% | -4.1% |
Q1 2022 | $50,834,000 | -13.6% | 700,000 | 0.0% | 0.10% | -8.5% |
Q4 2021 | $58,863,000 | +5.3% | 700,000 | +12.9% | 0.11% | -3.6% |
Q3 2021 | $55,918,000 | +125.6% | 620,000 | +138.5% | 0.11% | +124.5% |
Q2 2021 | $24,791,000 | +17.7% | 260,000 | +40.5% | 0.05% | +14.0% |
Q1 2021 | $21,064,000 | -8.1% | 185,000 | +11.8% | 0.04% | -14.0% |
Q4 2020 | $22,910,000 | +574.8% | 165,500 | +272.1% | 0.05% | +525.0% |
Q3 2018 | $3,395,000 | -86.5% | 44,476 | -86.4% | 0.01% | -86.2% |
Q2 2018 | $25,175,000 | +0.9% | 327,500 | -33.1% | 0.06% | 0.0% |
Q1 2018 | $24,944,000 | +400.3% | 489,203 | +355.1% | 0.06% | +427.3% |
Q4 2017 | $4,986,000 | -50.3% | 107,500 | -43.0% | 0.01% | -54.2% |
Q3 2017 | $10,040,000 | -65.4% | 188,500 | -59.7% | 0.02% | -66.2% |
Q2 2017 | $29,036,000 | +204.9% | 467,500 | +232.7% | 0.07% | +195.8% |
Q1 2017 | $9,523,000 | -78.4% | 140,500 | -77.6% | 0.02% | -80.2% |
Q4 2016 | $44,190,000 | -8.2% | 628,500 | -7.4% | 0.12% | -9.0% |
Q3 2016 | $48,133,000 | +54.1% | 678,500 | +6.3% | 0.13% | +56.5% |
Q2 2016 | $31,229,000 | +2.0% | 638,500 | +32.1% | 0.08% | +2.4% |
Q1 2016 | $30,610,000 | -18.2% | 483,500 | +45.0% | 0.08% | -15.3% |
Q4 2015 | $37,412,000 | -11.4% | 333,500 | -23.9% | 0.10% | -16.2% |
Q3 2015 | $42,232,000 | -34.0% | 438,500 | -29.8% | 0.12% | -26.9% |
Q2 2015 | $63,994,000 | +8.5% | 625,000 | -34.2% | 0.16% | +11.1% |
Q1 2015 | $58,986,000 | +26.0% | 950,000 | -11.0% | 0.14% | +25.2% |
Q4 2014 | $46,812,000 | -21.2% | 1,066,826 | +1.6% | 0.12% | -21.8% |
Q3 2014 | $59,430,000 | -24.6% | 1,050,000 | -40.2% | 0.15% | -27.9% |
Q2 2014 | $78,870,000 | -12.4% | 1,756,968 | -4.6% | 0.20% | -17.1% |
Q1 2014 | $89,996,000 | – | 1,840,783 | – | 0.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |